<DOC>
	<DOCNO>NCT02175771</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety fluticasone propionate inhalation powder 2 strength fluticasone propionate/salmeterol inhalation powder 2 strength administer Teva MDPI device 26 week patient persistent asthma</brief_summary>
	<brief_title>Long-Term Safety Study Fluticasone Propionate ( Fp ) Multidose Dry Powder Inhaler ( MDPI ) Fluticasone Propionate/Salmeterol ( FS ) MDPI Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Best prebronchodilator FEV1 great 40 % predict normal value . 2 . Patients must treatment regimen include shortacting β2 agonist ( SABA ) ( albuterol ) use need either inhale corticosteroid ( ICS ) ICS/longacting β2 agonist ( LABA ) preventative treatment minimum 8 week SV . Patients currently take lowdose ICS without LABA eligible study . Patients currently take lowdose ICS/LABA may enter mid ICS strength . All patient must maintain stable dose ICS ICS/LABA 4 week prior SV ( preSV necessary ) 1 qualify dos 3 . To meet reversibility disease criterion , patient must demonstrate ≥12 % reversibility FEV1 ( 200 mL patient aged18 year old ) within 30 minute follow 4 inhalation albuterol SV . Historic reversibility within past 12 month SV may use meet criterion . 4 . Written inform consent/assent obtain . For adult patient ( age 18 year old , applicable per local regulation ) , write informed consent form ( ICF ) must sign dated patient conduct studyrelated procedure . For minor patient ( age 12 17 year , applicable per local regulation ) , write ICF must sign dated parent/legal guardian write assent form must sign dated patient ( applicable ) conduct studyrelated procedure . Note : Age requirement specify local regulation . 5 . Outpatient &gt; = 12 year age date consent/assent . . 6 . Asthma diagnosis : The patient diagnosis asthma define National Institutes Health ( NIH ) . The asthma diagnosis present minimum 3 month stable ( defined exacerbation change medication ) least 30 day provide informed consent . 7 . The patient able perform acceptable repeatable spirometry . 8 . The patient able perform peak expiratory flow ( PEF ) handheld peak flow meter . 9 . The patient able use metereddose inhaler ( MDI ) device without spacer device MDPI device . 10 . The patient able withhold ( judged investigator ) regimen ICS study drug , rescue medication least 6 hour SV treatment visit spirometry perform . 11 . The patient/parent/legal guardian/caregiver capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement . 12 . SABAs : All patient must able replace current SABA albuterol/salbutamol HFA inhalation aerosol SV use need duration study . 13 . Female patient may pregnant , breastfeed , attempt become pregnant . Other criterion may apply , please contact investigator information 1 . The patient history lifethreatening asthma exacerbation define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure . 2 . The patient pregnant lactating , plan become pregnant study period 30 day study . 3 . The patient participate randomized patient investigational drug study within 30 day precede SV ( prescreening visit , applicable ) plan participate another investigational drug study time study . 4 . The patient previously participate Fp MDPI FS MDPI study . 5 . The patient know hypersensitivity corticosteroid , salmeterol , excipients study drug rescue medication formulation ( ie , lactose ) . 6 . The patient treat know strong cytochrome P450 ( CYP ) 3A4 inhibitor ( eg , azole antifungal , ritonavir , clarithromycin ) within 30 day SV plan treat strong CYP3A4 inhibitor study . 7 . The patient treat prohibited medication prescribe ( per protocol ) washout period SV . 8 . The patient currently smoke smoke history 10 packyears ( packyear define smoke 1 pack cigarettes/day 1 year ) . The patient may use tobacco product within past year ( eg , cigarette , cigar , chew tobacco , pipe tobacco ) . 9 . The patient culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve least 2 week SV . 10 . The patient history alcohol drug abuse within 2 year precede SV . 11 . The patient asthma exacerbation require systemic corticosteroid within 30 day SV , hospitalization asthma within 2 month SV . 12 . Initiation dose escalation immunotherapy ( administer route ) plan study period . However , patient initiate immunotherapy 90 day SV stable ( maintenance ) dose 30 day SV may consider inclusion . 13 . The patient use immunosuppressive medication within 4 week SV . 14 . The patient unable tolerate unwilling comply appropriate washout period withhold applicable medication . ( Patients require continuous treatment βblockers , monoamine oxidase inhibitor , tricyclic antidepressant , anticholinergic , and/or systemic corticosteroid exclude ) . 15 . The patient untreated oral candidiasis SV . Patients clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study . 16 . The patient history positive test human immunodeficiency virus , active hepatitis B virus , hepatitis C infection . 17 . The patient either employee immediate relative employee clinical investigational center . 18 . A member patient 's household participate study time . However , enrol patient completes discontinues participation study , another patient household may screen . 19 . The patient disease/condition medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . Other criterion may apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>